PTC Therapeutics Inc. (NASDAQ:PTCT) saw strong trading volume on Wednesday . 1,288,864 shares were traded during trading, an increase of 46% from the previous session’s volume of 883,933 shares.The stock last traded at $7.37 and had previously closed at $6.86.

Several equities research analysts have recently commented on the company. Royal Bank Of Canada restated a “sector perform” rating and set a $9.00 price target on shares of PTC Therapeutics in a research note on Monday, April 18th. Cowen and Company restated a “hold” rating on shares of PTC Therapeutics in a research note on Sunday, April 17th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $39.00 price objective on shares of PTC Therapeutics in a report on Sunday, April 17th. Zacks Investment Research lowered PTC Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 7th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating on shares of PTC Therapeutics in a report on Friday, May 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $36.13.

The company’s market cap is $251.34 million. The company’s 50 day moving average price is $7.22 and its 200-day moving average price is $11.75.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($1.22) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.04. The firm earned $18.90 million during the quarter, compared to analysts’ expectations of $13.74 million. During the same quarter last year, the firm earned ($1.15) EPS. The business’s revenue for the quarter was up 152.0% compared to the same quarter last year. On average, equities research analysts expect that PTC Therapeutics Inc. will post ($4.95) EPS for the current year.

A number of hedge funds and institutional investors have recently modified their holdings of PTCT. Jennison Associates purchased a new position in shares of PTC Therapeutics during the third quarter worth approximately $17,806,000. California State Teachers Retirement System increased its position in shares of PTC Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 62,719 shares of the biopharmaceutical company’s stock worth $2,032,000 after buying an additional 1,100 shares during the period. Rhumbline Advisers increased its position in shares of PTC Therapeutics by 8.1% in the fourth quarter. Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company’s stock worth $1,077,000 after buying an additional 2,485 shares during the period. ProShare Advisors LLC increased its position in shares of PTC Therapeutics by 10.6% in the fourth quarter. ProShare Advisors LLC now owns 32,490 shares of the biopharmaceutical company’s stock worth $1,053,000 after buying an additional 3,122 shares during the period. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its stake in shares of PTC Therapeutics by 82.2% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 204,392 shares of the biopharmaceutical company’s stock worth $6,622,000 after buying an additional 92,190 shares in the last quarter.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.